Pitcairn CO Uni Qure N.V. Transaction History

Pitcairn CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$20.24 - $36.01 $153,297 - $272,739	-7,574 Closed	0 $0
Q3 2021 Nov 10, 2021	BUY	$26.01 - $38.22 $4,135 - $6,076	159 Added 2.14%	7,574 $242,000
Q2 2021 Aug 11, 2021	BUY	$29.97 - $37.17 $32,996 - $40,924	1,101 Added 17.44%	7,415 $228,000
Q1 2021 May 10, 2021	SELL	$29.24 - $42.03 $2,426 - $3,488	-83 Reduced 1.3%	6,314 $213,000
Q4 2020 Feb 05, 2021	BUY	$35.35 - $50.67 $16,296 - $23,358	461 Added 7.77%	6,397 $231,000
Q3 2020 Nov 03, 2020	BUY	$35.98 - $47.66 $213,577 - $282,909	5,936 New	5,936 $218,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Pitcairn CO, based on Form 13F filings with the SEC.

Stay updated on Pitcairn CO with notifications on news.